Hyloris Pharmaceuticals SA (HYL.BR)
EUR 5.8
(-1.36%)
EUR 5.8
(-1.36%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -14.98 Million EUR | -72.37% |
| 2022 | -11.43 Million EUR | 3.44% |
| 2021 | -10.78 Million EUR | -86.62% |
| 2020 | -6.17 Million EUR | -174.77% |
| 2019 | -5.26 Million EUR | 63.33% |
| 2018 | -5.62 Million EUR | -57.64% |
| 2017 | -3.57 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q2 | -3.42 Million EUR | 0.0% |
| 2023 Q3 | -4.37 Million EUR | -27.55% |
| 2023 Q1 | -3.42 Million EUR | -2.74% |
| 2023 FY | - EUR | -72.37% |
| 2023 Q4 | -4.38 Million EUR | -0.42% |
| 2022 Q2 | -4.95 Million EUR | -108.23% |
| 2022 FY | - EUR | 3.44% |
| 2022 Q4 | -3.33 Million EUR | 0.0% |
| 2022 Q3 | -3.33 Million EUR | 32.75% |
| 2022 Q1 | -2.38 Million EUR | 5.01% |
| 2021 FY | - EUR | -86.62% |
| 2021 Q4 | -2.5 Million EUR | 39.11% |
| 2021 Q3 | -4.11 Million EUR | -75.49% |
| 2021 Q2 | -2.34 Million EUR | -130.11% |
| 2021 Q1 | -1.01 Million EUR | -43.69% |
| 2020 Q2 | -1.65 Million EUR | -25.23% |
| 2020 FY | - EUR | -174.77% |
| 2020 Q4 | -709.5 Thousand EUR | 0.0% |
| 2020 Q1 | -1.32 Million EUR | -159.35% |
| 2020 Q3 | -709.5 Thousand EUR | 57.21% |
| 2019 Q2 | -526 Thousand EUR | 3.31% |
| 2019 Q3 | -510.49 Thousand EUR | 2.95% |
| 2019 Q1 | -544 Thousand EUR | 0.0% |
| 2019 FY | - EUR | 63.33% |
| 2019 Q4 | -510.49 Thousand EUR | 0.0% |
| 2018 FY | - EUR | -57.64% |
| 2017 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -355.319% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 88.754% |
| Adocia SA | -22.73 Million EUR | 34.102% |
| Aelis Farma SA | -6.34 Million EUR | -136.017% |
| Biophytis S.A. | -13.8 Million EUR | -8.519% |
| Advicenne S.A. | -6.24 Million EUR | -139.91% |
| genOway Société anonyme | 6.35 Million EUR | 335.878% |
| IntegraGen SA | -52.5 Thousand EUR | -28431.703% |
| Medesis Pharma S.A. | -3.84 Million EUR | -289.609% |
| Neovacs S.A. | -8.44 Million EUR | -77.288% |
| NFL Biosciences SA | -4.04 Million EUR | -269.94% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 20753.523% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -421.319% |
| Sensorion SA | -22.31 Million EUR | 32.867% |
| Theranexus Société Anonyme | -7.38 Million EUR | -102.782% |
| TME Pharma N.V. | -5.07 Million EUR | -195.347% |
| Valbiotis SA | -6.95 Million EUR | -115.385% |
| TheraVet SA | -517.33 Thousand EUR | -2795.604% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | 20.808% |
| argenx SE | -199.5 Million EUR | 92.491% |
| BioSenic S.A. | -6.79 Million EUR | -120.424% |
| Celyad Oncology SA | -7.76 Million EUR | -92.967% |
| DBV Technologies S.A. | -79.53 Million EUR | 81.165% |
| Galapagos NV | 51.03 Million EUR | 129.351% |
| Genfit S.A. | -28.05 Million EUR | 46.597% |
| GeNeuro SA | -14.31 Million EUR | -4.626% |
| Innate Pharma S.A. | -7.57 Million EUR | -97.677% |
| Inventiva S.A. | -101.84 Million EUR | 85.292% |
| MaaT Pharma SA | -19.74 Million EUR | 24.113% |
| MedinCell S.A. | -20.04 Million EUR | 25.272% |
| Nanobiotix S.A. | -34.01 Million EUR | 55.966% |
| Onward Medical N.V. | -35.23 Million EUR | 57.484% |
| Oryzon Genomics S.A. | -4.43 Million EUR | -237.893% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | 35.614% |
| Oxurion NV | -16.72 Million EUR | 10.455% |
| Pharming Group N.V. | 4.98 Million EUR | 400.745% |
| Poxel S.A. | -12.17 Million EUR | -22.999% |
| GenSight Biologics S.A. | -21.73 Million EUR | 31.063% |
| Transgene SA | -27.02 Million EUR | 44.568% |
| Financière de Tubize SA | 184.57 Thousand EUR | 8216.118% |
| UCB SA | 1.26 Billion EUR | 101.18% |
| Valneva SE | -64.51 Million EUR | 76.781% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 47.166% |